Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 927-931

  Nakagawa, Mayumi ^a   Stites, Daniel P ^b   Farhat, Sepidch ^b   Sisler, Jerry R ^b   Moss, Bernard ^b   Kong, Francis ^b   Moscicki, Anna Barbara ^b   Palefsky, Joel M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ADULT; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL ARTICLE; CONDYLOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0030934907     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513992     Document Type: Article

References (15)

1. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:415-28.
2. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986;58:611-6.
3. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
4. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110-4.
5. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
6. Meneguzzi G, Cemi C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991;181:62-9.
7. Moscicki AB, Palefsky J, Smith G, Siboski S, Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993;82:578-85.
8. Ting Y, Manos MM. Detection and typing of genital human papillomaviruses. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols and applications. San Diego: Academic Press, 1990:356-67.
9. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988;53:539-47.
10. Earl PL, Moss B. Generation of recombinant vaccinia viruses. In: Ausubel FM, Brent R, Kingston RE, et al., eds. Current protocols in molecular biology. Vol 2. New York: Greene Publishing Associates & Wiley Interscience, 1991:16.17.1-16.
11. Nonnenmacher B, Hubbert NL, Kimbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.
12. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-43.
13. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-20.
14. Nakagawa M, Stites DP, Farhat S, et al. T cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol 1996;3:205-10.
15. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996;17:131-7.